FINANCIAL TIES BETWEEN COMPAniesproducingaddictive tobacco productsandcompaniesproducing drugs to treat or alleviate the addiction are a potential conflict of interest.Several typesof financial tiescanexist. For example, one company could be the sole supplier of a product that is needed by another company. Or, a company could be financially dependent on sales fromanothercompany.Corporatediversi...

BACKGROUND Most European health care systems are suffering from the impact of demographic change. In short, aging of society is leading to higher costs of treatment per capita, while reproduction rates below 2.1 children per woman lead to a reduced number of younger people to provide for the necessary contributions into the health insurance system.This research paper addresses the questions wha...

In today’s competitive world, there are several strategies to deal with the fast changing environment, among which New product development (NPD) is a common strategy. However, almost half of the resources that companies devote to NPD are spent on products that may fail. This issue is particularly highlighted in the pharmaceutical industry mainly because of a long development-time, low success r...

OBJECTIVE Access to medicines has long been and remains a challenge in African countries. The impact of medicines registration policies in these countries poses a challenge for pharmaceutical companies wanting to register medicines in these countries. The recent AMRHI (African Medicines Registration Harmonisation Initiative) has increased the focus on the need for harmonisation. Medicines regis...

The life sciences are transforming pharmaceutical companies in terms of both internal R&D processes and strategies for external knowledge capture mergers, acquisitions, strategic alliances and licensing. Dr. Mittra’s research on life science innovation and the pharmaceutical industry reveals that these are a cluster of related activities that provide various strategic options for managing innov...

Effective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines. Increasingly, drug donations have been established by drug companies, but these are often limited in time, place or use. Measures exist which are more sustainable and will have ...